Wire · regulatory
Eli Lilly sues 6 companies over illegal retatrutide sales
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 August 2026 · Fusion42 review
Eli Lilly is suing six U.S. companies for illegally selling unapproved black-market versions of its experimental weight loss drug retatrutide, which remains in Phase 3 trials and has not been approved for human use. The company alleges these sales violate regulatory laws, and it has reported over 200 offenders to legal and regulatory authorities.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 12 Aug 2026 and 13 Aug 2026.
◆ ◆ The Wire takeaway
Enforcement against illegal sales of unapproved drugs is intensifying with legal actions targeting sellers of experimental weight loss treatments. You must tighten regulatory compliance and monitor supply chains to avoid exposure to unapproved product risks.
◆ Coverage
2 sources · first reported 12 Aug 2026 · latest 13 Aug 2026
◆ Related on Wire
◆ Topics